Wegovy Lawsuits Allege Stomach Paralysis, Thousands of Claims Expected

Lawsuits are being filed against Novo Nordisk, the manufacturer of the diet drug Wegovy, alleging that it caused gastroparesis or stomach paralysis in users, resulting in long-term gastrointestinal side effects. The multidistrict litigation, involving thousands of claims, will scrutinize the allegations and may lead to changes in the marketing and prescription of Wegovy and similar GLP-1 receptor agonist drugs like Ozempic and Mounjaro." This description focuses on the primary topic of the lawsuits against Novo Nordisk, the main entity being the manufacturer of Wegovy, and the context of the multidistrict litigation. It also highlights the significant actions and consequences of the allegations, including the potential impact on the pharmaceutical industry and public health. The objective details provided will guide the AI in creating an accurate visual representation of the article's content, such as images related to the drug, the manufacturer, and the legal proceedings.

author-image
Aqsa Younas Rana
New Update
Wegovy Lawsuits Allege Stomach Paralysis, Thousands of Claims Expected

Wegovy Lawsuits Allege Stomach Paralysis, Thousands of Claims Expected

Lawsuits filed in the US District Court for the Eastern District of Pennsylvania allege that the diet drug Wegovy caused gastroparesis or stomach paralysis in users, resulting in long-term gastrointestinal side effects. Thousands of claims are expected to be transferred to the litigation.

Why this matters: The allegations of stomach paralysis and long-term gastrointestinal side effects associated with Wegovy have significant implications for the pharmaceutical industry and public health, as millions of people may be affected by these drugs. The outcome of these lawsuits could lead to changes in the way these drugs are marketed and prescribed, and may also impact the development of similar medications in the future.

The lawsuits claim that Novo Nordisk, the manufacturer of Wegovy, failed to warn users and doctors about the true risk of gastroparesis, which is dose-specific, meaning the higher the dose, the more likely stomach paralysis would occur. One such lawsuit was filed by Jenny Bryant, a New York woman, who alleges that she required surgery to empty the contents of her stomach due to side effects of the weight loss drug.

Bryant's complaint, filed on April 23, presents claims against Novo Nordisk for negligence, failure to warn, defective design, and deceptive and unfair marketing practices. Wegovy is a higher dose version of the diabetes drug Ozempic, which has been widely prescribed as a diet drug in recent years.

The Wegovy lawsuits are part of the federal court multidistrict litigation (MDL) No. 3094, IN RE GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS (GLP-1 RAS) PRODUCTS LIABILITY LITIGATION. This MDL includes cases involving gastrointestinal and stomach problems linked to Wegovy, Rybelsus, and Ozempic, all of which contain semaglutide as the active ingredient.

The U.S. Judicial Panel on Multidistrict Litigation (JPML) decided to centralize all gastroparesis lawsuits involving users of Wegovy, Ozempic, or other similar medications in the U.S. District Court for the Eastern District of Pennsylvania. The litigation is expected to involve thousands of claims, with estimates suggesting that nearly 2% of the U.S. population has been prescribed one of the GLP-1 medications either for diabetes treatment or weight loss.

A science day is scheduled for June 14, 2024, where the parties will review information on the gastroparesis risks associated with Wegovy, Ozempic, and other GLP-1 drugs. Lawyers are pursuing lawsuits over these drugs causing gastroparesis or stomach paralysis, which can leave users with long-term gastrointestinal side effects.

Wegovy, a weekly injectable drug developed by Danish company Novo Nordisk, has been credited with spurring incredible weight loss transformations. However, a new long-term study suggests the drug might not be as effective as the hype makes it seem, with patients losing only 10% of their original body weight after four years on the medication. For someone who is severely obese, this may not be enough to protect them from health issues associated with severe obesity.

The average price of Wegovy in the US without insurance is $1,350 per month. Other options like Ozempic, Mounjaro, and Zepbound are similarly expensive, running from $935 to $1,059 per month. Wegovy and Zepbound aren't currently covered by many insurers in the US, while Ozempic and Mounjaro might have more insurance options since they were originally approved to treat diabetes.

As the Wegovy lawsuits move forward in the federal MDL, the allegations of stomach paralysis and long-term gastrointestinal side effects will be closely scrutinized. With thousands of claims expected, the litigation could have significant implications for Novo Nordisk and the future of GLP-1 receptor agonist drugs like Wegovy, Ozempic, and Mounjaro.

Key Takeaways

  • Lawsuits allege Wegovy caused gastroparesis (stomach paralysis) in users, resulting in long-term GI side effects.
  • Thousands of claims expected to be transferred to the litigation, with significant implications for the pharma industry.
  • Manufacturer Novo Nordisk accused of failing to warn users and doctors about the true risk of gastroparesis.
  • The litigation includes cases involving Wegovy, Ozempic, and Mounjaro, all containing semaglutide as the active ingredient.
  • A science day is scheduled for June 14, 2024, to review information on gastroparesis risks associated with these drugs.